Related Experiment Video
Updated: Mar 19, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Drug Development for Metastasis Prevention
Yari Fontebasso1, Steven M Dubinett1
1Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Abstract:
Metastatic disease is responsible for 90% of death from solid tumors. However, only a minority of metastasis-specific targets has been exploited therapeutically, and effective prevention and suppression of metastatic disease is still an elusive goal. In this review, we will first summarize the current state of knowledge about the molecular features of the disease, with particular focus on steps and targets potentially amenable to therapeutic intervention. We will then discuss the reasons underlying the paucity of metastatic drugs in the current oncological arsenal and potential ways to overcome this therapeutic gap. We reason that the discovery of novel promising targets, an increased understanding of the molecular features of the disease, the effect of disruptive technologies, and a shift in the current preclinical and clinical settings have the potential to create more successful drug development endeavors.
Insights
Metastatic disease causes most cancer deaths, yet few drugs target it. This review explores molecular features, therapeutic targets, and strategies to overcome the drug development gap for better cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Metastatic disease accounts for 90% of solid tumor deaths.
- Effective therapeutic strategies for preventing and suppressing metastasis remain limited.
- Few metastasis-specific molecular targets have been successfully translated into clinical treatments.
Purpose of the Study:
- To review the current understanding of the molecular characteristics of metastatic disease.
- To identify potential therapeutic targets within the metastatic cascade.
- To analyze the reasons for the scarcity of anti-metastasis drugs and propose solutions.
Main Methods:
- Literature review of current research on metastatic disease.
- Analysis of molecular pathways involved in metastasis.
- Discussion of preclinical and clinical drug development challenges.
Main Results:
- Identified key molecular features and potential therapeutic targets in metastasis.
- Highlighted the significant gap in anti-metastasis drugs within current cancer therapies.
- Discussed factors contributing to the slow development of these drugs.
Conclusions:
- Advancing the development of anti-metastasis drugs requires novel target discovery.
- A deeper understanding of metastatic molecular biology is crucial.
- Disruptive technologies and adapted preclinical/clinical settings can improve drug development success.
More Related Videos
Related Concept Videos
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...